Literature DB >> 20737162

Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Arnd Heiligenhaus1, Stephan Thurau, Maren Hennig, Rafael S Grajewski, Gerhild Wildner.   

Abstract

BACKGROUND: Endogenous uveitis is a sight-threatening disease. In addition to corticosteroids, immunosuppressive agents are commonly used to treat patients with severe course. Immunosuppressive drugs act nonspecifically, rather than providing a specific interaction with the critical pathogenetic pathways of uveitis. Better knowledge of the basic mechanisms underlying uveitis and of the molecules that are important for regulating inflammation has helped to create new and more specific treatment approaches. Biological therapy for inflammatory diseases employs substances that interfere with specific molecules or pathways induced in the body during the inflammatory process.
METHODS: This review gives an overview on molecules that play a critical role in the pathogenetic process of uveitis, as has been observed in patients or the respective animal models, and summarizes the current experience with biologicals for the treatment of uveitis refractive to conventional immunosuppressives.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20737162     DOI: 10.1007/s00417-010-1485-8

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  202 in total

1.  Expression of functional ICAM-1 and VCAM-1 adhesion molecules by an immortalized epithelial cell clone derived from the small intestine.

Authors:  X C Li; A M Jevnikar; D R Grant
Journal:  Cell Immunol       Date:  1997-01-10       Impact factor: 4.868

2.  Endotoxin-induced uveitis in the rat.

Authors:  J V Forrester; B V Worgul; G R Merriam
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1980

Review 3.  Interleukin-17.

Authors:  F Fossiez; J Banchereau; R Murray; C Van Kooten; P Garrone; S Lebecque
Journal:  Int Rev Immunol       Date:  1998       Impact factor: 5.311

4.  Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.

Authors:  P S Linsley; P M Wallace; J Johnson; M G Gibson; J L Greene; J A Ledbetter; C Singh; M A Tepper
Journal:  Science       Date:  1992-08-07       Impact factor: 47.728

5.  Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis.

Authors:  Sumru Onal; Haluk Kazokoglu; Aylin Koc; Sule Yavuz
Journal:  Ocul Immunol Inflamm       Date:  2008 Sep-Oct       Impact factor: 3.070

6.  Intermediate uveitis: long-term course and visual outcome.

Authors:  N Vidovic-Valentincic; A Kraut; M Hawlina; S Stunf; A Rothova
Journal:  Br J Ophthalmol       Date:  2008-12-09       Impact factor: 4.638

7.  Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis.

Authors:  Takeru Yoshimura; Koh-Hei Sonoda; Nobuyuki Ohguro; Yoshiyuki Ohsugi; Tatsuro Ishibashi; Daniel J Cua; Takashi Kobayashi; Hiroki Yoshida; Akihiko Yoshimura
Journal:  Rheumatology (Oxford)       Date:  2009-01-22       Impact factor: 7.580

8.  Interferon-alpha2a and Vogt-Koyanagi-Harada disease: a double-edged sword?

Authors:  Valerie Touitou; Damien Sene; Christine Fardeau; Thi-Huong-Du Boutin; Pierre Duhaut; Jean-Charles Piette; Phuc LeHoang; Patrice Cacoub; Bahram Bodaghi
Journal:  Int Ophthalmol       Date:  2007-02-23       Impact factor: 2.029

9.  Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

Authors:  N Nishimoto; N Miyasaka; K Yamamoto; S Kawai; T Takeuchi; J Azuma
Journal:  Ann Rheum Dis       Date:  2008-11-19       Impact factor: 19.103

10.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

View more
  16 in total

1.  Anti-inflammatory effect of Heliotropium indicum Linn on lipopolysaccharide-induced uveitis in New Zealand white rabbits.

Authors:  Samuel Kyei; George Asumeng Koffuor; Paul Ramkissoon; Elvis Ofori Ameyaw; Emmanuel Akomanin Asiamah
Journal:  Int J Ophthalmol       Date:  2016-04-18       Impact factor: 1.779

Review 2.  Novel Therapies in Development for Diabetic Macular Edema.

Authors:  Aniruddha Agarwal; Rubbia Afridi; Muhammad Hassan; Mohammad Ali Sadiq; Yasir J Sepah; Diana V Do; Quan Dong Nguyen
Journal:  Curr Diab Rep       Date:  2015-10       Impact factor: 4.810

3.  [DOG and BVA guideline no. 24b : Noninfectious uveitis posterior].

Authors: 
Journal:  Ophthalmologe       Date:  2017-12       Impact factor: 1.059

4.  Mucosal inflammation in spondylarthritides: past, present, and future.

Authors:  Liesbet Van Praet; Filip Van den Bosch; Herman Mielants; Dirk Elewaut
Journal:  Curr Rheumatol Rep       Date:  2011-10       Impact factor: 4.592

5.  Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation.

Authors:  Wei Cheng Liang; Jia Lin Ren; Qiu Xiao Yu; Jian Li; Tsz Kin Ng; Wai Kit Chu; Yong Jie Qin; Kai On Chu; Andrew V Schally; Chi Pui Pang; Sun On Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-02       Impact factor: 11.205

6.  Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.

Authors:  Aswani Dutt Vadlapudi; Ashaben Patel; Kishore Cholkar; Ashim K Mitra
Journal:  Recent Pat Biomed Eng       Date:  2012-04-01

7.  Understanding autoimmunity in the eye: from animal models to novel therapies.

Authors:  Rachel R Caspi
Journal:  Discov Med       Date:  2014-03       Impact factor: 2.970

8.  Surveying uveitis specialists-a call for consensus.

Authors:  Emmett T Cunningham
Journal:  J Ophthalmic Inflamm Infect       Date:  2012-03-28

9.  Red eyes presenting with a fistulous lesion in the left lower extremity: a case report.

Authors:  Natalia Palmou Fontana; Enrique Judez Navarro; Oscar Martín Melero; Sergio Losa Palacios
Journal:  J Med Case Rep       Date:  2015-09-11

10.  An anti-interleukin-2 receptor drug attenuates T- helper 1 lymphocytes-mediated inflammation in an acute model of endotoxin-induced uveitis.

Authors:  Salvador Mérida; María Sancho-Tello; Amparo Navea; Inmaculada Almansa; María Muriach; Francisco Bosch-Morell
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.